299 related articles for article (PubMed ID: 37901240)
21. Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK; Owen KL; Zanker D; Spurling A; Rautela J; Duivenvoorden HM; Baschuk N; Caramia F; Loi S; Darcy PK; Lim E; Parker BS
Cancer Immunol Res; 2017 Oct; 5(10):871-884. PubMed ID: 28848054
[TBL] [Abstract][Full Text] [Related]
22. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
23. Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.
Czirr E; Leuchtenberger S; Dorner-Ciossek C; Schneider A; Jucker M; Koo EH; Pietrzik CU; Baumann K; Weggen S
J Biol Chem; 2007 Aug; 282(34):24504-13. PubMed ID: 17573346
[TBL] [Abstract][Full Text] [Related]
24. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
[TBL] [Abstract][Full Text] [Related]
25. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
26. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
28. Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
Zhao Q; He X; Qin X; Liu Y; Jiang H; Wang J; Wu S; Zhou R; Yu C; Liu S; Zhang H; Tian M
Front Immunol; 2022; 13():938439. PubMed ID: 35812418
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
30. Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator.
Yin T; Wang G; Ye T; Wang Y
Sci Rep; 2016 Jan; 6():19534. PubMed ID: 26777116
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
32. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
33. Phenylboronic acid modified lipid nanocarriers mediated co-delivery of immunocytokine TRAIL and gamma-secretase inhibitor to triple negative breast cancer cells and cancer stem cells.
Pindiprolu SKSS; Avasarala H; Dinakaran SK
Med Hypotheses; 2021 Dec; 157():110716. PubMed ID: 34731681
[TBL] [Abstract][Full Text] [Related]
34. Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
Ren Z; Xue Y; Liu L; Zhang X; Pei J; Zhang Y; Wang Y; Yu K
Cancer Lett; 2023 Jul; 565():216221. PubMed ID: 37192729
[TBL] [Abstract][Full Text] [Related]
35. A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling.
Das A; Narayanam MK; Paul S; Mukhnerjee P; Ghosh S; Dastidar DG; Chakrabarty S; Ganguli A; Basu B; Pal M; Chatterji U; Banerjee SK; Karmakar P; Kumar D; Chakrabarti G
J Biol Chem; 2019 Apr; 294(17):6733-6750. PubMed ID: 30824542
[TBL] [Abstract][Full Text] [Related]
36. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.
Li G; Hu J; Cho C; Cui J; Li A; Ren P; Zhou J; Wei W; Zhang T; Liu X; Liu W
Cell Signal; 2023 Sep; 109():110729. PubMed ID: 37257766
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
38. Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression.
Siddharth S; Parida S; Muniraj N; Hercules S; Lim D; Nagalingam A; Wang C; Gyorffy B; Daniel JM; Sharma D
Elife; 2021 Dec; 10():. PubMed ID: 34889737
[TBL] [Abstract][Full Text] [Related]
39. The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells.
Pamarthy S; Jaiswal MK; Kulshreshtha A; Katara GK; Gilman-Sachs A; Beaman KD
Oncotarget; 2015 Oct; 6(33):34206-20. PubMed ID: 26418877
[TBL] [Abstract][Full Text] [Related]
40. Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer.
Niavarani SR; St-Cyr G; Daniel L; Lawson C; Giguère H; Alkayyal AA; Tai LH
Front Immunol; 2023; 14():1098344. PubMed ID: 36860852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
